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ABSTRACT
Vogt–Koyanagi–Harada disease is rare, mediated by autoimmune melanocyte inflammation and facilitated by genetic predisposition[1-3]. 
The main clinical features include uveitis, meningitis, tinnitus and sensorineural deafness, and skin and hair depigmentation. It usually 
develops in four consecutive stages: prodromal, acute uveitic, convalescent, and chronic or recurrent[4]. In view of the first two stages, the 
differential diagnosis takes into account uveo-meningeal syndromes. Treatment is based on high dose corticosteroids. We present the case 
of a 14-year-old girl admitted to hospital with fever, progressive uveo-meningeal symptoms, and sensorineural hearing loss. After work-up, 
the final diagnosis of Vogt–Koyanagi–Harada disease was made. 
LEARNING POINTS
• Vogt–Koyanagi–Harada disease should be considered when a patient presents with uveo-meningeal syndromes, particularly in 
pigmented ethnic groups.
• Acute bilateral uveitis should raise suspicion of Vogt–Koyanagi–Harada disease. 
• Early stage diagnosis leads to prompt appropriate treatment and improves patient outcomes.
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CASE DESCRIPTION
A 14-year-old girl was referred to the emergency department with a 72-hour history of fever and progressive weakness and malaise. Her 
past medical history did not reveal any remarkable symptoms, suggesting a viral infection. Born in Ecuador, South America, she was living in 
Spain, with no history of travelling outside the country for the previous 8 years. Any other epidemiologic circumstances, as well as family or 
personal past medical history, toxic habits, allergies or treatments were not relevant.
Physical examination showed a deteriorated general condition and weakness with normal osteo-tendon reflexes. Vital signs were the 
following: 32 breaths per minute, 101 heart beats per minute, BP 100/60 mmHg, temperature 39 ºC, and 96% base SpO2. A very slight 
unspecific rash was observed on both legs. 
Emergency department laboratory work-up highlighted alanine transaminase 112 U/L (7-34); gamma-glutamyltransferase 141 U/L (4-24); 
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C-reactive protein 150.3 mg/L (0.02-5); lactate dehydrogenase 415 U/L (0-247); haemoglobin 9.3 g/dL; haematocrit 27.4%; 80% neutrophils; 
75,000 platelets; prothrombin time 17’’ (10.4-13), 59% (70-130); and activated partial thromboplastin time 50’’ (26-37). Chest X-ray showed 
a diffuse bilateral interstitial infiltrate. Urine sample and ECG were normal.
After admittance to our Internal Medicine Department, the course of the first week was characterized by evening mild fevers, with no 
determinant symptoms or signs. Complementary tests for systemic autoimmune, infectious and oncological diseases were negative or 
within normal values (Table 1).
Infectious diseases
• Serology
 Blood: Rapid plasma reagin test; Cytomegalovirus (CMV); Epstein-Barr virus; 
Toxoplasmosis; HIV; Parvovirus; Mumps virus; Influenza A and B virus; Varicella 
zoster virus (VZV); Herpes simplex virus (HSV); Measles virus; Toscana virus; Hepatitis 
viruses B and C; Legionella; Coxiella burnetti, Chlamydia; Streptococcus pneumoniae; 
Mycoplasma pneumoniae; Borrelia; Brucella; Leishmania; Trypanosoma cruzi; and 
Bartonella henselae
 Nasopharyngeal swabs: Respiratory syncytial virus (RSV); Influenza A and B
• Tuberculin skin test and interferon gamma release assays (IGRA)
• Bacterial and fungal cultures in blood, urine and sputum samples
• Löwenstein-Jensen culture in blood and sputum samples
• Parasite study in faecal sample
Systemic inflammatory diseases
Antinuclear antibodies; rheumatoid factor; citrulline antibody; antineutrophil cytoplasmic 
antibodies; angiotensin-converting enzyme; HLA-B antigens 27 and 51
Oncological (mainly haematological neoplasms)
Immunophenotypic analysis of peripheral blood; immunoglobulins; beta-2-microglobulin; light 
chain proteins and electrophoresis
Imaging procedures (infectious, systemic inflammatory or oncological diseases)
Chest X-ray; abdominal ultrasound; echocardiography
Table 1. Complementary tests performed for differential diagnosis
On day 8 of admission, the patient developed acute blurred vision and meningeal symptoms. Examination of the pertinent fundus revealed 
an acute bilateral anterior uveitis (Fig. 1). 
Figure 1. Acute bilateral anterior uveitis
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In addition, a lumbar puncture was performed showing normal pressure, normal glucose levels and lymphocytic pleocytosis in aseptic 
cerebrospinal fluid (CSF). Both findings were consistent with the diagnosis of uveo-meningeal syndrome, which led to further tests. Cranial 
and ocular nuclear magnetic resonance imaging, bronchoscopy and positron emission tomography showed no evidence of sarcoidosis, 
granulomatosis, infective or malignant lymphoproliferative disease, and the patient did not meet the diagnostic criteria of the International 
Workshop on Ocular Sarcoidosis. 
On day 10 of admission, sudden hearing loss and tinnitus appeared. Audiometry showed a bilateral sensorineural deafness (Right: 45 dB, 
Left: 35 dB). 
With these data – including uveo-meningeal syndrome and sensorineural hearing loss – and after ruling out any other infectious, systemic 
autoimmune, oncological diseases as well as any clinical evidence of Cogan syndrome, there was a high suspicion of Vogt–Koyanagi–Harada 
(VKH) disease. Based on the International Committee on Nomenclature for VKH and the positive test for HLA-DRB1 and HLA-DR4, the 
diagnosis of incomplete VKH disease was finally made. 
In addition to the topical treatment for acute uveitis, oral prednisone (1 mg/kg/day: 45 mg/day) was initiated for 1 week, followed by a weekly 
tapering dose of 5 mg, until the dose of 35 mg (0.75 mg/kg) was reached and maintained for 6 months. Then, a new weekly tapering dose of 5 
mg was initiated until its total discontinuation. The patient improved with complete resolution of symptoms, remaining asymptomatic after 
1-year follow-up, without the appearance of skin or hair depigmentation.
DISCUSSION 
VKH is an uncommon entity, affecting more women than men in the third to fourth decades of life, particularly in pigmented ethnic groups 
(Asian, Hispanic, Native American and Middle Eastern). 
The accumulated evidence suggests that a viral environmental factor triggers in a genetically predisposed individual, as shown by the strong 
association with HLA antigens (DR4)[3], an autoimmune aggression against proteins of pigmented cells, due to molecular mimicry[1]. This 
leads to an aberrant inflammatory response affecting tissues and structures containing melanocytes[2] – eye, inner ear, central nervous 
system and skin – allowing for the clinical and pathogenic manifestations to develop into four phases: 
I. Prodromal: This phase lasts 1 week and is clinically characterized by flu-like and meningeal symptoms (fever, headache, meningism). Its 
mayor sign is the pleocytosis in CSF. 
II. Acute uveitic: This phase also lasts 1 week and is clinically characterized by acute blurred vision, hearing loss and tinnitus, along with 
acute bilateral uveitis (typically, posterior uveitis with exudative retinal detachments) and sensorineural deafness. 
III. Convalescent: This phase can last for months or years and is characterized by asymptomatic skin and hair depigmentation, developing 
alopecia, poliosis, vitiligo and choroid depigmentation (sunset glow sign). 
IV. Chronic or recurrent: This phase is characterized by complications of recurrent uveitis, atrophy and iris depigmentation[4]. The absence 
of this last stage establishes the denomination of incomplete VHK disease. Since this denomination generates doubts on the accuracy of the 
diagnosis and may delay the prompt instauration of treatment, thus compromising the outcomes, some authors have sought to change this 
denomination[5].
This case was challenging because of the large number of medical conditions associated with uveitis and uveo-meningeal syndromes as well 
as the rare entity that VKH is itself, but also because of the age of the patient and the unusual clinical presentation, especially concerning the 
atypical and late onset of uveitis.
Even though VKH disease is rarely observed in Europe, globalization and immigration of different ethnic groups convey uncommon diseases, 
of which physicians should be aware.
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